1. Pink Sheet
  3. >>Europe

Experts Want To Drop Confusing Terminology For Decentralized Clinical Trials

 
• By Vibha Sharma

A new scientific paper drawn up by experts on behalf of the EU public-private Trials@Home project discusses the pros and cons of various terms being used to refer to decentralized clinical trials and suggests a unified way forward.

Woman discussing with doctor through tablet PC at home
A wide range of terminology has evolved to describe trials in which activities are centered around participants • Source: Alamy

While there is a growing interest in the adoption of decentralized elements in clinical trials, in which activities are centered around study participants rather than investigator sites, the lack of standardized terminology for such research can hamper meaningful discussions on this front.

A new

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

More from Geography

Recent and Upcoming FDA Advisory Committee Meetings

 
• By Sue Sutter

Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.

UK Health Data Research Service Looks ‘Encouraging’ For Industry, But Implementation Details Will Be Key

 
• By Anabel Costa-Ferreira

Marcus Vass and Vladimir Murovec of international law firm Osborne Clarke tell the Pink Sheet what the government's planned HDRS might mean for industry, and how it compares with the European Health Data Space.

EU Health Data Space May Speed Up R&D Through Access To Multi-Omics & Clinical Record Data

 
• By Eliza Slawther

The European Health Data Space framework will allow companies to accelerate R&D processes and identify new molecular targets faster by facilitating centralized access to certain types of high-quality data, Finland’s Orion Pharma says.